Idelalisib
As of the edition of 20 October 2026, Idelalisib is a small molecule: marketed, first approved in 2014 (US); acts on PIK3CD; US protection ends in 2033.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Small molecule
- Brand name
- Zydelig
- First approved
- 23 July 2014 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Gilead Sciences; 2 holders in all
- Registered trials
- 57, 30 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Digestive system; Lungs and airways
US protection
US protection ends in 2033.
The last listed US drug-substance patent ends in 2033. The application that gives this date is held by Gilead Sciences.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product6 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 6 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Idelalisib.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PIK3CD | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | O00329 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 3 | 0 | 1 |
| Phase 1 | 16 | 7 | 1 | 8 |
| Phase 2 | 26 | 11 | 2 | 13 |
| Phase 3 | 8 | 1 | 0 | 7 |
| Phase 4 | 2 | 0 | 1 | 1 |
| All trials | 57 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Originator, Applicant and Lead sponsor of trials | 2014 to now |